Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.35 – $0.75
38% from low
Exchange
OTC Link
ADRC
Borrow rate
10.97%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.2M | $45.3M | $105.5M | $176.8M | $1.26B | $2.24B | $1.95B | $1.41B |
| Cost of revenue | $584.0K | $5.8M | $14.1M | $13.2M | $255.0M | $408.9M | $939.0M | $860.4M |
| Gross profit | $12.6M | $39.6M | $91.4M | $163.6M | $1.00B | $1.83B | $1.01B | $547.0M |
| Gross margin | 95.6% | 87.3% | 86.6% | 92.5% | 79.7% | 81.7% | 51.8% | 38.9% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $354.3M | $112.2M |
| Operating income | −$23.0K | $372.0K | −$3.8M | −$66.1M | −$160.0M | −$618.3M | −$289.1M | −$237.0M |
| EBITDA | $696.0K | $3.7M | $5.8M | −$39.5M | $31.8M | $322.3M | −$111.1M | −$32.8M |
| Net income | $155.0K | $1.2M | $581.0K | −$61.9M | −$229.2M | −$835.7M | −$5.5M | −$1.02B |
| Net margin | 1.2% | 2.6% | 0.6% | -35.0% | -18.2% | -37.3% | -0.3% | -72.7% |
| EPS (diluted) | -0.01 | 0.01 | 0.00 | -0.37 | -0.93 | -3.12 | -0.00 | -3.59 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.6B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $1.7B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
BICO GROUP AB UNSP/ADR
No one on the platform currently holds BCCOY.
No tracked institution reports a position in BCCOY as of their last filing.
No one on the platform has traded BCCOY yet.
| $135M |
| — |
| NDTPNDT Pharmaceuticals Inc. | $0.35 | -26.16% | $56M | — |
| NGENFNervGen Pharma Corp. | $3.95 | -2.47% | $313M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 0.2× historical median P/S.
Fair value ≈ $1.19 · price $0.50 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.